Prevalence of Pituitary Hormone Dysfunction, Metabolic Syndrome, and Impaired Quality of Life in Retired Professional Football Players: A Prospective Study
Abstract
Hypopituitarism is common after moderate and severe traumatic brain injury (TBI). Herein, we address the association between mild TBI (mTBI) and pituitary and metabolic function in retired football players. Retirees 30–65 years of age, with one or more years of National Football League (NFL) play and poor quality of life (QoL) based on Short Form 36 (SF-36) Mental Component Score (MCS) were prospectively enrolled. Pituitary hormonal and metabolic syndrome (MetS) testing was performed. Using a glucagon stimulation test, growth hormone deficiency (GHD) was defined with a standard cut point of 3 ng/mL and with a more stringent body mass index (BMI)-adjusted cut point. Subjects with and without hormonal deficiency (HD) were compared in terms of QoL, International Index of Erectile Function (IIEF) scores, metabolic parameters, and football career data. Of 74 subjects, 6 were excluded because of significant non-football-related TBIs. Of the remaining 68 subjects (mean age, 47.3±10.2 years; median NFL years, 5; median NFL concussions, 3; mean BMI, 33.8±6.0), 28 (41.2%) were GHD using a peak GH cutoff of <3 ng/mL. However, with a BMI-adjusted definition of GHD, 13 of 68 (19.1%) were GHD. Using this BMI-adjusted definition, overall HD was found in 16 (23.5%) subjects: 10 (14.7%) with isolated GHD; 3 (4.4%) with isolated hypogonadism; and 3 (4.4%) with both GHD and hypogonadism. Subjects with HD had lower mean scores on the IIEF survey (p=0.016) and trended toward lower scores on the SF-36 MCS (p=0.113). MetS was present in 50% of subjects, including 5 of 6 (83%) with hypogonadism, and 29 of 62 (46.8%) without hypogonadism (p=0.087). Age, BMI, median years in NFL, games played, number of concussions, and acknowledged use of performance-enhancing steroids were similar between HD and non-HD groups. In summary, in this cohort of retired NFL players with poor QoL, 23.5% had HD, including 19% with GHD (using a BMI-adjusted definition), 9% with hypogonadism, and 50% had MetS. Although the cause of HD is unclear, these results suggest that GHD and hypogonadism may contribute to poor QoL, erectile dysfunction, and MetS in this population. Further study of pituitary function is warranted in athletes sustaining repetitive mTBI.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Langlois J., Rutland-Brown W., and Wald M. (2006). The epidemiology and impact of traumatic brain injury: a brief overview. J. Head Trauma Rehabil. 21, 375–378.
2.
McCrea M., Hammeke T., Olsen G., Leo P., and Guskiewicz K. (2004). Unreported concussion in high school football players: implications for prevention. Clin. J. Sport Med. 14, 13–17.
3.
Casson I.R. (2010). Twelve years of National Football League concussion data. Sports Health 2, 471–483.
4.
Casson I.R., Viano D.C., Powell J.W., and Pellman E.J. (2011). Repeat concussions in the National Football League. Sports Health 3, 11–24.
5.
Guskiewicz K., Marshall S., Bailes J., McCrea M., Cantu R., Randolph C., and Jordan B. (2005). Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 57, 719–726.
6.
Guskiewicz K., Marshall S., Bailes J., McCrea M., Harding H. Jr., Matthews A., Mihalik J., and Cantu R. (2007). Recurrent concussion and risk of depression in retired professional football players. Med. Sci. Sports Exerc. 39, 903–909.
7.
Agha A., Rogers B., Sherlock M., O'Kelly P., Tormey W., Phillips J., and Thompson C.J. (2004). Anterior pituitary dysfunction in survivors of traumatic brain injury. J. Clin. Endocrinol. Metab. 89, 4929–4936.
8.
Aimaretti G., Ambrosio M.R., Di Somma C., Fusco A., Cannavo S., Gasperi M., Scaroni C., De Marinis L., Benvenga S., degli Uberti E.C., Lombardi G., Mantero F., Martino E., Giordano G., and Ghigo E. (2004). Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin. Endocrinol. (Oxf.) 61, 320–326.
9.
Aimaretti G., Ambrosio M.R., Di Somma C., Gasperi M., Cannavo S., Scaroni C., Fusco A., Del Monte P., De Menis E., Faustini-Fustini M., Grimaldi F., Logoluso F., Razzore P., Rovere S., Benvenga S., Degli Uberti E.C., De Marinis L., Lombardi G., Mantero F., Martino E., Giordano G., and Ghigo E. (2005). Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J. Clin. Endocrinol. Metab. 90, 6085–6092.
10.
Bondanelli M., De Marinis L., Ambrosio M.R., Monesi M., Valle D., Zatelli M.C., Fusco A., Bianchi A., Farneti M., and degli Uberti E.C. (2004). Occurrence of pituitary dysfunction following traumatic brain injury. J. Neurotrauma 21, 685–696.
11.
Herrmann B.L., Rehder J., Kahlke S., Wiedemayer H., Doerfler A., Ischebeck W., Laumer R., Forsting M., Stolke D., and Mann K. (2006). Hypopituitarism following severe traumatic brain injury. Exp. Clin. Endocrinol. Diabetes 114, 316–321.
12.
Kelly D.F., Gonzalo I.T., Cohan P., Berman N., Swerdloff R., and Wang C. (2000). Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J. Neurosurg. 93, 743–752.
13.
Leal-Cerro A., Flores J.M., Rincon M., Murillo F., Pujol M., Garcia-Pesquera F., Dieguez C., and Casanueva F.F. (2005). Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury. Clin. Endocrinol. (Oxf.) 62, 525–532.
14.
Lieberman S.A., Oberoi A.L., Gilkison C.R., Masel B.E., and Urban R.J. (2001). Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J. Clin. Endocrinol. Metab. 86, 2752–2756.
15.
Tanriverdi F., Senyurek H., Unluhizarci K., Selcuklu A., Casanueva F.F., and Kelestimur F. (2006). High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. J. Clin. Endocrinol. Metab. 91, 2105–2111.
16.
Ware J. Jr., and Sherbourne C. (1992). The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473–483.
17.
Ware J.E., and Kosinski M. (2001). SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. Quality Metric Inc.: Lincoln, RI.
18.
Bavisetty S., McArthur D., Dusick J., Wang C., Cohan P., Boscardin W., Swerdloff R., Levin H., Chang D., and Muizelaar J. (2008). Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. Neurosurgery 62, 1080–1093.
19.
Ives J.C., Alderman M., and Stred S.E. (2007). Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male. J. Athl. Train. 42, 431–439.
20.
Bondanelli M., Ambrosio M., Zatelli M., De Marinis L., and degli Uberti E. (2005). Hypopituitarism after traumatic brain injury. Eur. J. Endocrinol. 152, 679–691.
21.
Tanriverdi F., Unluhizarci K., Coksevim B., Selcuklu A., Casanueva F., and Kelestimur F. (2007). Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism. Clin. Endocrinol. (Oxf.) 66, 360–366.
22.
Tanriverdi F., Unluhizarci K., Karaca Z., Casanueva F., and Kelestimur F. (2010). Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers. Pituitary 13, 111–114.
23.
Kelestimur F., Tanriverdi F., Atmaca H., Unluhizarci K., Selcuklu A., and Casanueva F. (2004). Boxing as a sport activity associated with isolated GH deficiency. J. Endocrinol. Invest. 27, RC28–RC32.
24.
Horn S., Gregory P., and Guskiewicz K. (2009). Self-reported anabolic-androgenic steroids use and musculoskeletal injuries: findings from the center for the study of retired athletes health survey of retired NFL players. Am. J. Phys. Med. Rehabil. 88, 192–200.
25.
Kerr Z., Marshall S., and Guskiewicz K. (2012). Reliability of concussion history in former professional football players. Med. Sci. Sports Exerc. 44, 377–382.
26.
Qoubaitary A., Swerdloff R.S., and Wang C. (2005). Advances in male hormone substitution therapy. Exp. Opin. Pharmacother. 6, 1493–1506.
27.
Qu X., Gaw G.I., Al Sayed M., Cohan P., Christenson P., Swerdloff R., Kelly D., and Wang C. (2005). Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests. J. Clin. Endocrinol. Metab. 90, 1563–1569.
28.
Vahl N., Jørgensen J., Skjaerbaek C., Veldhuis J., Orskov H., and Christiansen J. (1997). Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am. J. Physiol. 272, E1108–E1116.
29.
Bredella M.A., Torriani M., Thomas B.J., Ghomi R.H., Brick D.J., Gerweck A.V., and Miller K.K. (2009). Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J. Clin. Endocrinol. Metab. 94, 3995–4002.
30.
Scacchi M., Orsini F., Cattaneo A., Grasso A., Filippini B., Pecori G.F., Fatti L., Moro M., and Cavagnini F. (2010). The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis. Eur. J. Endocrinol. 163, 201–206.
31.
Molitch M., Clemmons D., Malozowski S., Merriam G., and Vance M. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587–1609.
32.
Cook D., Yuen K., Biller B., Kemp S., and Vance M. (2009). American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients—2009 update: executive summary of recommendations. Endocr. Pract. 15, 580–586.
33.
Yuen K., Biller B., Molitch M., and Cook D. (2009). Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J. Clin. Endocrinol. Metab. 94, 2702–2707.
34.
Bonert V., Elashoff J., Barnett P., and Melmed S. (2004). Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J. Clin. Endocrinol. Metab. 89, 3397–3401.
35.
Corneli G., Di Somma C., Baldelli R., Rovere S., Gasco V., Croce C., Grottoli S., Maccario M., Colao A., and Lombardi G. (2005). The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. 153, 257–264.
36.
Gómez J., Espadero R., Escobar-Jiménez F., Hawkins F., Picó A., Herrera-Pombo J., Vilardell E., Durán A., Mesa J. and Faure E. (2002). Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin. Endocrinol. 56, 329–334.
37.
Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., and Smith S.C. Jr. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645.
38.
Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., and Pena B.M. (1999). Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int. J. Impot. Res. 11, 319–326.
39.
Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., and Wicker P.A. (1998). Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338, 1397–1404.
40.
Guskiewicz K., McCrea M., Marshall S., Cantu R., Randolph C., Barr W., Onate J., and Kelly J. (2003). Cumulative effects associated with recurrent concussion in collegiate football players: the NCAA Concussion Study. JAMA 290, 2549–2555.
41.
Hoffman D.M., Nguyen T.V., O'Sullivan A.J., Baxter R.C., and Ho K.K. (1994). Diagnosis of growth hormone deficiency in adults. Lancet 344, 482–483.
42.
Leong K., Walker A., Martin I., Wile D., Wilding J., and MacFarlane I. (2001). An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin. Endocrinol. (Oxf.) 54, 463–468.
43.
Berg C., Meinel T., Lahner H., Yuece A., Mann K., and Petersenn S. (2010). Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur. J. Endocrinol. 162, 477–482.
44.
Conceição F., Fisker S., Andersen M., Kaal A., Jørgensen J., Vaisman M., and Christiansen J. (2003). Evaluation of growth hormone stimulation tests in cured acromegalic patients. Growth Horm. IGF Res. 13, 347–352.
45.
Agha A., Sherlock M., Phillips J., Tormey W., and Thompson C.J. (2005). The natural history of post-traumatic neurohypophysial dysfunction. Eur. J. Endocrinol. 152, 371–377.
46.
Popovic V., Pekic S., Pavlovic D., Maric N., Jasovic-Gasic M., Djurovic B., Medic Stojanoska M., Zivkovic V., Stojanovic M., Doknic M., Milic N., Djurovic M., Dieguez C., and Casanueva F.F. (2004). Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. J. Endocrinol. Invest. 27, 1048–1054.
47.
Dubourg J., and Messerer M. (2011). Sports-related chronic repetitive head trauma as a cause of pituitary dysfunction. Neurosurg. Focus 31, E2.
48.
Tanriverdi F., De Bellis A., Bizzarro A., Sinisi A., Bellastella G., Pane E., Bellastella A., Unluhizarci K., Selcuklu A., and Casanueva F. (2008). Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity? Eur. J. Endocrinol. 159, 7–13.
49.
Abs R., Mattsson A.F., Bengtsson B.A., Feldt-Rasmussen U., Goth M.I., Koltowska-Haggstrom M., Monson J.P., Verhelst J., and Wilton P. (2005). Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth. Horm. IGF Res. 15, 349–359.
50.
Alexander G.M., Swerdloff R.S., Wang C., Davidson T., McDonald V., Steiner B., and Hines M. (1998). Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm. Behav. 33, 85–94.
51.
Bengtsson B.A., Eden S., Lonn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tolli J., Sjostrom L., and Isaksson O.G. (1993). Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76, 309–317.
52.
Blum W.F., Shavrikova E.P., Edwards D.J., Rosilio M., Hartman M.L., Marin F., Valle D., van der Lely A.J., Attanasio A.F., Strasburger C.J., Henrich G., and Herschbach P. (2003). Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. J. Clin. Endocrinol. Metab. 88, 4158–4167.
53.
Deijen J.B., de Boer H., Blok G.J., and van der Veen E.A. (1996). Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology 21, 313–322.
54.
Feldt-Rasmussen U., Wilton P., and Jonsson P. (2004). Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth. Horm. IGF Res. 14, Suppl A, S51–S58.
55.
Giusti M., Meineri I., Malagamba D., Cuttica C.M., Fattacciu G., Menichini U., Rasore E., and Giordano G. (1998). Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. Eur. J. Clin. Invest. 28, 13–19.
56.
Hellawell D.J., Taylor R.T., and Pentland B. (1999). Cognitive and psychosocial outcome following moderate or severe traumatic brain injury. Brain Inj. 13, 489–504.
57.
Howell S., and Shalet S. (2001). Testosterone deficiency and replacement. Horm. Res. 56, Suppl 1, 86–92.
58.
Karlberg J., Mattsson L.A., and Wiklund I. (1995). A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet. Gynecol. Scand. 74, 367–372.
59.
Koltowska-Haggstrom M., Hennessy S., Mattsson A.F., Monson J.P., and Kind P. (2005). Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Horm. Res. 64, 46–54.
60.
Levin H.S., Gary H.E. Jr., Eisenberg H.M., Ruff R.M., Barth J.T., Kreutzer J., High W.M. Jr., Portman S., Foulkes M.A., Jane J.A., and et al. (1990). Neurobehavioral outcome 1 year after severe head injury. Experience of the Traumatic Coma Data Bank. J. Neurosurg. 73, 699–709.
61.
Gotherstrom G., Svensson J., Koranyi J., Alpsten M., Bosaeus I., Bengtsson B., and Johannsson G. (2001). A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. 86, 4657–4665.
62.
Wang C., Jackson G., Jones T.H., Matsumoto A.M., Nehra A., Perelman M.A., Swerdloff R.S., Traish A., Zitzmann M., and Cunningham G. (2011). Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669–1675.
63.
Corona G., Mannucci E., Petrone L., Balercia G., Paggi F., Fisher A.D., Lotti F., Chiarini V., Fedele D., Forti G., and Maggi M. (2007). NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J. Sex. Med. 4, 1038–1045.
64.
Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., and Salonen J.T. (2005). The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J. Clin. Endocrinol. Metab. 90, 712–719.
65.
Brand J.S., van der Tweel I., Grobbee D.E., Emmelot-Vonk M.H., and van der Schouw Y.T. (2010). Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol. 40, 189–207.
66.
Hong J.W., Kim J.Y., Kim Y.E., and Lee E.J. (2011). Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm. Metab. Res. 43, 48–54.
67.
Attanasio A.F., Mo D., Erfurth E.M., Tan M., Ho K.Y., Kleinberg D., Zimmermann A.G., and Chanson P. (2010). Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J. Clin. Endocrinol. Metab. 95, 74–81.
68.
Di Somma C., Pivonello R., Pizza G., De Rosa A., Lombardi G., Colao A., and Savastano S. (2010). Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J. Endocrinol. Invest. 33, 171–177.
69.
Oliveira C.R., Meneguz-Moreno R.A., Aguiar-Oliveira M.H., and Barreto-Filho J.A. (2011). Emerging role of the GH/IGF-I on cardiometabolic control. [Article in English, Portuguese, Spanish] Arq. Bras. Cardiol. 97, 434–439.
70.
Akanji A.O., and Smith R.J. (2012). The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab. Syndr. Relat. Disord. 10, 3–13.
71.
Allan C.A., and McLachlan R.I. (2010). Androgens and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17, 224–232.
72.
Kerr Z., Marshall S., Harding H. Jr., and Guskiewicz K. (2012). Nine-year risk of depression diagnosis increases with increasing self-reported concussions in retired professional football players. Am. J. Sports Med. 40, 2206–2212.
73.
Gysland S., Mihalik J., Register-Mihalik J., Trulock S., Shields E., and Guskiewicz K. (2012). The relationship between subconcussive impacts and concussion history on clinical measures of neurologic function in collegiate football players. Ann. Biomed. Eng. 40, 14–22.
74.
Arwert L.I., Deijen J.B., Muller M., and Drent M.L. (2005). Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm. Behav. 47, 343–349.
75.
Arwert L.I., Veltman D.J., Deijen J.B., Lammertsma A.A., Jonker C., and Drent M.L. (2005). Memory performance and the growth hormone/insulin-like growth factor axis in elderly: a positron emission tomography study. Neuroendocrinology 81, 31–40.
76.
Mahajan T., Crown A., Checkley S., Farmer A., and Lightman S. (2004). Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur. J. Endocrinol. 151, 325–332.
77.
Mukherjee A., Tolhurst-Cleaver S., Ryder W.D., Smethurst L., and Shalet S.M. (2005). The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy. J. Clin. Endocrinol. Metab. 90, 1542–1549.
78.
Soares C.N., Musolino N.R., Cunha Neto M., Caires M.A., Rosenthal M.C., Camargo C.P., and Bronstein M.D. (1999). Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. Arq. Neuropsiquiatr. 57, 182–189.
79.
Svensson J., Mattsson A., Rosen T., Wiren L., Johannsson G., Bengtsson B.A., Koltowska Haggstrom M., and Swedish K.N.B. (2004). Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth. Horm. IGF Res. 14, 207–215.
80.
Wiren L., Bengtsson B.A., and Johannsson G. (1998). Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin. Endocrinol. (Oxf.) 48, 613–620.
81.
Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto A.M., Snyder P.J., Weber T., Berman N., Hull L., and Swerdloff R.S. (2004). Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 2085–2098.
Information & Authors
Information
Published In
Copyright
Copyright 2014, Mary Ann Liebert, Inc.
History
Published online: 3 July 2014
Published in print: July 1, 2014
Published ahead of print: 8 May 2014
Published ahead of production: 19 February 2014
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.